Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1981 1
1982 4
1985 7
1987 2
1988 1
1994 1
1996 2
1997 1
1998 2
2004 1
2007 2
2008 2
2009 4
2010 1
2011 1
2012 2
2013 1
2014 3
2015 1
2018 2
2019 1
2021 2
2022 2
2023 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
Spiegel DM, Farmer B, Smits G, Chonchol M. Spiegel DM, et al. J Ren Nutr. 2007 Nov;17(6):416-22. doi: 10.1053/j.jrn.2007.08.005. J Ren Nutr. 2007. PMID: 17971314 Clinical Trial.
OBJECTIVE: This study was designed to evaluate the efficacy of magnesium carbonate as a phosphate binder in hemodialysis patients. DESIGN: This study was a prospective, randomized, open-label trial comparing magnesium carbonate/calcium carbonate versus …
OBJECTIVE: This study was designed to evaluate the efficacy of magnesium carbonate as a phosphate binder in hemodialysis patie …
Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial.
Tzanakis IP, Papadaki AN, Wei M, Kagia S, Spadidakis VV, Kallivretakis NE, Oreopoulos DG. Tzanakis IP, et al. Int Urol Nephrol. 2008;40(1):193-201. doi: 10.1007/s11255-007-9300-0. Epub 2008 Jan 10. Int Urol Nephrol. 2008. PMID: 18193489 Free PMC article. Clinical Trial.
The aim of this study was to evaluate the efficacy and safety of magnesium carbonate (MgCO(3)) as a phosphate-binder in hemodialysis patients. METHODS: Forty-six stable hemodialysis patients were randomly allocated to receive either MgCO(3) (n=25) or calcium carbona …
The aim of this study was to evaluate the efficacy and safety of magnesium carbonate (MgCO(3)) as a phosphate-binder in hemodi …
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Ruospo M, et al. Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3. Cochrane Database Syst Rev. 2018. PMID: 30132304 Free PMC article.
The remaining studies evaluated comparisons between sevelamer (hydrochloride or carbonate), sevelamer plus calcium, lanthanum, iron (ferric citrate, sucroferric oxyhydroxide, stabilised polynuclear iron(III)-oxyhydroxide), calcium (acetate, ketoglutarate, carbonate), bixalomer, c …
The remaining studies evaluated comparisons between sevelamer (hydrochloride or carbonate), sevelamer plus calcium, lanthanum, iron (ferric …
Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study.
Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Delmez JA, et al. Kidney Int. 1996 Jan;49(1):163-7. doi: 10.1038/ki.1996.22. Kidney Int. 1996. PMID: 8770963 Free article. Clinical Trial.
In short-term studies, we showed that magnesium carbonate (MgCO3) was well-tolerated and controlled P and Mg levels when given in conjunction with a dialysate Mg of 0.6 mg/dl. ...
In short-term studies, we showed that magnesium carbonate (MgCO3) was well-tolerated and controlled P and Mg levels when given …
Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study.
Spiegel DM, Farmer B. Spiegel DM, et al. Hemodial Int. 2009 Oct;13(4):453-9. doi: 10.1111/j.1542-4758.2009.00364.x. Epub 2009 May 12. Hemodial Int. 2009. PMID: 19469885 Clinical Trial.
Seven chronic hemodialysis patients participated in this open label, prospective pilot study to evaluate the effects of a magnesium-based phosphate binder on coronary artery calcification (CAC) scores and vertebral bone mineral density (V-BMD) in patients with baseline CAC scores …
Seven chronic hemodialysis patients participated in this open label, prospective pilot study to evaluate the effects of a magnesium-based ph …
Pharmacokinetic and Bioequivalence Evaluation of Dihydroxyaluminum Aminoacetate, Heavy Magnesium Carbonate, and Aspirin Tablets in Healthy Chinese Subjects in the Fasting and Postprandial Conditions.
Yao F, He Y, Lu P, Wang J, Xie Y, Li X, Liu Q, Liu Y, Cao D, Liang J, Liu G. Yao F, et al. Clin Pharmacol Drug Dev. 2024 Oct;13(10):1157-1163. doi: 10.1002/cpdd.1455. Epub 2024 Jul 31. Clin Pharmacol Drug Dev. 2024. PMID: 39081255 Clinical Trial.
Dihydroxyaluminum aminoacetate, heavy magnesium carbonate, and aspirin tablets is a new combined aspirin preparation, each containing aspirin (81 mg), dihydroxyaluminum aminoacetate (11 mg), and heavy magnesium carbonate (22 mg). ...
Dihydroxyaluminum aminoacetate, heavy magnesium carbonate, and aspirin tablets is a new combined aspirin preparation, each con …
Comparative Efficacy and Acceptability of 12 Phosphorus-Lowering Drugs in Adults with Hyperphosphatemia and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
Luo H, Feng J, Xue G, Zhang Y, Li Y, Huang X, Chen X, You S, Dong H, Li L, Li J, Xiao H, Ai X, Li X, Huang B. Luo H, et al. Blood Purif. 2023;52(7-8):609-620. doi: 10.1159/000531577. Epub 2023 Aug 17. Blood Purif. 2023. PMID: 37591223
In terms of efficacy, except for niacinamide, all drugs lowered the level of serum phosphorus compared with placebo, with mean difference ranging between -1.61 (95% credible interval [CrI], -2.60 to -0.62) mg/dL for magnesium carbonate and -0.85 (-1.66 to -0.05) mg/ …
In terms of efficacy, except for niacinamide, all drugs lowered the level of serum phosphorus compared with placebo, with mean difference ra …
Bone and vascular effects of magnesium supplements in CKD patients (the MagicalBone Pilot Study).
Pendón-Ruiz de Mier MV, Santamaría R, Moyano-Peregrín C, Gordillo JE, Salmoral-Chamizo A, López-López I, Rodelo-Haad C, Valle C, Membrives-González C, López-Ruiz DJ, Álvarez-Benito M, López-Baltanás R, Torralbo AI, Valdés-Díaz KC, García-Sáez RM, Jurado-Montoya D, Pinaglia-Tobaruela G, Martínez-Moreno JM, Martín-Malo A, Soriano S, Rodríguez M, Rodríguez-Ortiz ME, Muñoz-Castañeda JR. Pendón-Ruiz de Mier MV, et al. Nefrologia (Engl Ed). 2024 Sep-Oct;44(5):721-730. doi: 10.1016/j.nefroe.2024.11.001. Nefrologia (Engl Ed). 2024. PMID: 39547778 Free article. Clinical Trial.
A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.
Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, Ponce P, Marzell B, de Francisco AL. Covic A, et al. Nephrol Dial Transplant. 2013 Sep;28(9):2383-92. doi: 10.1093/ndt/gft203. Epub 2013 Jun 19. Nephrol Dial Transplant. 2013. PMID: 23787550 Free PMC article. Clinical Trial.
The objective of this post hoc evaluation of the CALcium acetate MAGnesium carbonate (CALMAG) study was to compare the effects of calcium acetate/magnesium carbonate (CaMg) and a calcium-free phosphate binder, sevelamer-hydrochloride (HCl), on serum le …
The objective of this post hoc evaluation of the CALcium acetate MAGnesium carbonate (CALMAG) study was to compare the effects …
48 results